NATH BIOGENES (INDIA)
|
NATH BIOGENES (INDIA) Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2013 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 20.31 | 20.85 | 18.43 | -35.46 | 7.34 |
| CEPS(Rs) | 22.32 | 22.56 | 20.01 | -33.84 | 10.16 |
| DPS(Rs) | 2.00 | 2.00 | 2.00 | 2.00 | - |
| Book NAV/Share(Rs) | 339.08 | 320.94 | 301.61 | 285.16 | 35.91 |
| Tax Rate(%) | 4.89 | 4.68 | 3.19 | -6.23 | 4.48 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 13.69 | 15.02 | 16.25 | 13.37 | 14.45 |
| EBIT Margin(%) | 14.04 | 15.26 | 15.44 | -18.96 | 11.60 |
| Pre Tax Margin(%) | 11.12 | 12.50 | 12.00 | -22.79 | 8.93 |
| PAT Margin (%) | 10.58 | 11.91 | 11.62 | -24.21 | 8.53 |
| Cash Profit Margin (%) | 11.62 | 12.89 | 12.62 | -23.10 | 11.80 |
| Performance Ratios | |||||
| ROA(%) | 4.05 | 4.74 | 4.57 | -15.03 | 8.50 |
| ROE(%) | 6.15 | 6.70 | 6.28 | -22.48 | 22.76 |
| ROCE(%) | 6.89 | 7.26 | 7.09 | -14.84 | 23.88 |
| Asset Turnover(x) | 0.38 | 0.40 | 0.39 | 0.62 | 1.00 |
| Sales/Fixed Asset(x) | 1.32 | 1.22 | 1.12 | 1.62 | 2.08 |
| Working Capital/Sales(x) | 1.12 | 1.08 | 0.99 | 1.02 | 6.37 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.76 | 0.82 | 0.89 | 0.62 | 0.48 |
| Receivable days | 91.63 | 105.14 | 110.74 | 69.85 | 44.32 |
| Inventory Days | 284.23 | 240.40 | 259.30 | 195.06 | 189.43 |
| Payable days | -249.00 | -1,457.17 | 744.29 | 1,503.38 | -4,219.16 |
| Valuation Parameters | |||||
| PER(x) | 7.18 | 8.33 | 7.69 | - | - |
| PCE(x) | 6.53 | 7.70 | 7.08 | -6.31 | - |
| Price/Book(x) | 0.43 | 0.54 | 0.47 | 0.75 | - |
| Yield(%) | 1.37 | 1.15 | 1.41 | 0.94 | - |
| EV/Net Sales(x) | 0.85 | 1.09 | 1.12 | 1.78 | 0.24 |
| EV/Core EBITDA(x) | 5.70 | 7.18 | 6.79 | 12.65 | 1.60 |
| EV/EBIT(x) | 6.07 | 7.15 | 7.23 | -9.36 | 2.05 |
| EV/CE(x) | 0.41 | 0.50 | 0.50 | 0.78 | 0.21 |
| M Cap / Sales | 0.76 | 0.99 | 0.89 | 1.46 | - |
| Growth Ratio | |||||
| Net Sales Growth(%) | 9.71 | 10.37 | 8.26 | 102.15 | 11.13 |
| Core EBITDA Growth(%) | 7.76 | 2.11 | 26.77 | 90.81 | 31.43 |
| EBIT Growth(%) | 0.91 | 9.13 | 188.13 | -430.58 | 46.76 |
| PAT Growth(%) | -2.57 | 13.16 | 151.96 | -673.70 | 27.66 |
| EPS Growth(%) | -2.57 | 13.11 | 151.98 | -583.10 | 27.66 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.19 | 0.18 | 0.18 | 0.17 | 0.33 |
| Current Ratio(x) | 1.89 | 2.18 | 2.40 | 2.41 | 1.22 |
| Quick Ratio(x) | 0.96 | 1.30 | 1.44 | 1.27 | 0.43 |
| Interest Cover(x) | 4.81 | 5.52 | 4.49 | -4.96 | 4.35 |
| Total Debt/Mcap(x) | 0.44 | 0.33 | 0.39 | 0.23 | - |
Compare Financial Ratios of peers of NATH BIOGENES (INDIA)
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NATH BIOGENES (INDIA) | ₹314.3 Cr | -3.1% | -7.1% | -24.6% | Stock Analytics | |
| BOMBAY BURMAH TRADING CORPORATION | ₹13,507.8 Cr | -1.2% | 3.7% | -28.8% | Stock Analytics | |
| KAVERI SEED COMPANY | ₹6,090.6 Cr | 2.8% | 8.9% | 9.7% | Stock Analytics | |
| VENKYS (INDIA) | ₹2,143.8 Cr | 1.7% | 6.9% | -33.4% | Stock Analytics | |
| BOMBAY SUPER HYBRID SEEDS | ₹1,365.6 Cr | -3.8% | -2.4% | -30.1% | Stock Analytics | |
| INDO US BIOTECH | ₹288.1 Cr | -0.4% | -5.2% | -56.8% | Stock Analytics | |
NATH BIOGENES (INDIA) Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATH BIOGENES (INDIA) | -3.1% |
-7.1% |
-24.6% |
| SENSEX | 0.9% |
1.2% |
-0.4% |
You may also like the below Video Courses
